{"nctId":"NCT01042496","briefTitle":"Bipolar Depression Before and After Lamotrigine Treatment","startDateStruct":{"date":"2009-12"},"conditions":["Bipolar Depression"],"count":72,"armGroups":[{"label":"Bipolar Group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lamotrigine","Procedure: 1H-MR"]},{"label":"Control Group","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: 1H-MR"]}],"interventions":[{"name":"Lamotrigine","otherNames":["Lamictal®"]},{"name":"1H-MR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Bipolar Group Inclusion Criteria:\n\n* Diagnosis of Bipolar Type I or II disorder depress phase (SCID confirmed)\n* Moderate depression as confirmed by Montgomery Asberg Depression Rating Scale greater than or equal to 20\n* Negative urine toxicology screen\n* Negative urine pregnancy test\n* No clinically significant lab abnormalities for complete blood count (CBC), Thyroid stimulating hormone (TSH), Sodium (Na+), Potassium (K+), Chlorine (Cl-), Carbon dioxide (CO2), creatinine (CREA), blood urea nitrogen (BUN), Glucose, hepatic panel.\n\nBipolar Group Exclusion Criteria:\n\n* Inability to provide informed consent\n* Any current Axis I diagnosis other than anxiety disorders needing concurrent antidepressant therapy\n* History of active substance abuse/dependence within the last 3 months\n* History of claustrophobia\n* History of adverse reaction to Lamotrigine\n* Fluoxetine and decanoate antipsychotic therapy\n* Unwilling or unable to taper current sub-optimal psychotropic medications other than a stable dosage of Lithium, Depakote, or an Atypical Antipsychotic approved by study personnel\n* Unstable active medical illness\n* Pregnancy or breast-feeding\n* Male/ Female not practicing a reliable form of birth control (condom, Intrauterine Device (IUD), depo injection)\n* Female wishing to commence oral contraceptive therapy within 3 months of enrollment date (stable oral contraceptive therapy exception)\n* Active suicidal ideation with plan\n* History of major head trauma with loss of consciousness \\> 5 minutes or skull fracture\n* History of previous neurological event (epilepsy, stroke, transient ischemic attack)\n* Implanted metal objects (i.e., pacemakers, aneurysm clips, metal prostheses, joints, rods)\n* Inability to speak English\n* Prominent Axis II disorder \\[This will be assessed by the principal investigator, who has \\>10 years clinical experience with this population. Hospital discharge summaries and outpatient medical records will be reviewed for evidence that Axis II pathology is the primary psychiatric disturbance (i.e., adequate trials of mood stabilizing treatments with minimal to no response, prominent self injurious behavior in the absence of significant mood symptomatology, or atypical cycle patterns)\\].\n\nHealthy Control Group Inclusion Criteria:\n\n* Negative urine toxicology screen\n* Negative urine pregnancy test\n* Normal blood values for thyroid stimulating hormone (TSH)\n\nHealthy Control Group Exclusion Criteria:\n\n* Inability to provide informed consent\n* Any current Axis I or II diagnosis\n* Known history of claustrophobia\n* Lifetime personal or family history (first-degree relative) of dementia, substance-related disorder (nicotine abuse or dependence exception), psychotic disorder, mood disorder (history of bereavement exception), anxiety disorder (specific phobia exception)\n* Unstable active medical illness\n* Pregnancy or breast-feeding\n* Male /Female not practicing a reliable form of birth control (condom, IUD, depo injection)\n* History of major head trauma with loss of consciousness \\> 5 minutes or skull fracture\n* History of previous neurological event (epilepsy, stroke, transient ischemic attack)\n* Implanted metal objects (i.e., pacemakers, aneurysm clips, metal prostheses, joints)\n* Inability to speak English\n* On current medications known to affect glutamate (i.e., Riluzole).\n* Any medically remarkable impairment due to a medical condition or brain injury resulting in significant impairment in cognitive functioning based on neuropsychological test battery and/or MRS scan results.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline for Both Groups, and After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group","description":"The MADRS is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). A score of less than 12 is considered clinical remission of depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.79","spread":"5.80"},{"groupId":"OG001","value":"0.30","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.28","spread":"11.67"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Glutamate+Glutamine (GLX) Measured in Mid Anterior Cingulate Cortex (MACC) & Left Dorsal Lateral Prefrontal Cortex (LDLPC) Using Long TE PRESS MRS Technique at Baseline for Both Groups; After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group","description":"Two different MRS sequences were used to measure the brain chemicals in in anterior cingulate and left dorsal lateral prefrontal cortex : an intermediate echo-time PRESS sequence and a 2D J-resolved averaged PRESS sequence. (Note: The intermediate echo-time PRESS sequence was used for this outcome measure.) Spectroscopic data were inspected for quality; subjects whose data were contaminated by artifact were excluded from the study. Spectra were then processed using LCModel to quantify brain chemical levels. Regular brain MRI images were segmented, yielding a map of the amount of cerebrospinal fluid (CSF); the MRS voxel was overlaid onto the CSF map and the fraction of CSF was measured. This CSF corrected measurement was used for statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.08","spread":"3.88"},{"groupId":"OG001","value":"11.98","spread":"2.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.69","spread":"4.05"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"2.7"},{"groupId":"OG001","value":"12.9","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":"2.7"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"N-acetylaspartic Acid (NAA) Measured in the MACC and LDLPC Using the Long TE (TE80) PRESS MRS Technique at Baseline for Both Groups, and After 12 Weeks of Lamotrigine Monotherapy for the Bipolar (BP) Group and BP Responders and Non-responders","description":"Two different MRS sequences were used to measure the brain chemicals in a single 2 x 2 x 2 cm cube located in the center of anterior cingulate cortex: an intermediate echo-time PRESS sequence and a 2D J-resolved averaged PRESS sequence. (Note: The intermediate echo-time PRESS sequence was used for this outcome measure.) Spectroscopic data were inspected for quality; subjects whose data were contaminated by artifact were excluded from the study. Spectra were then processed using LCModel to quantify brain chemical levels. Regular brain MRI images were segmented, yielding a map of the amount of CSF in the head. The MRS voxel was overlaid onto the CSF map and the fraction of CSF within the voxel measured. This CSF-corrected measurement was used for statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"1.9"},{"groupId":"OG001","value":"20.1","spread":"1.5"},{"groupId":"OG002","value":"21.0","spread":"2.8"},{"groupId":"OG003","value":"20.0","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":"2.1"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"20.8","spread":"2.9"},{"groupId":"OG003","value":"20.5","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"2.9"},{"groupId":"OG001","value":"17.51","spread":"1.77"},{"groupId":"OG002","value":"15.2","spread":"3.3"},{"groupId":"OG003","value":"15.4","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"3.2"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"14.9","spread":"3.8"},{"groupId":"OG003","value":"14.5","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Mean Glutamate (GLU) Measured in the MACC and LDLPC Using the ProFit MRS Technique at Baseline for Both Groups, After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group","description":"Two different MRS sequences were used to measure the brain chemicals in a single 2 x 2 x 2 cm cube located in the center of anterior cingulate cortex: an intermediate echo-time PRESS sequence and a 2D J-resolved averaged PRESS sequence. (Note: The 2D J-resolved averaged PRESS sequence was used for this outcome measure.) Spectroscopic data were inspected for quality; subjects whose data were contaminated by artifact were excluded from the study. Spectra were then processed using LCModel to quantify brain chemical levels. Regular brain MRI images were segmented, yielding a map of the amount of CSF in the head. The MRS voxel was overlaid onto the CSF map and the fraction of CSF within the voxel measured. This CSF-corrected measurement was then used for statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.55","spread":"32.57"},{"groupId":"OG001","value":"157.51","spread":"36.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":"13.5"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":"15.5"},{"groupId":"OG001","value":"64.1","spread":"12.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"11.6"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Glutamine/Glutamate Ratio Measured in the LDLPC at Baseline Using the ProFit Magnetic Resonance Spectroscopy (MRS) Technique","description":"Two different MRS sequences were used to measure the brain chemicals in a single 2 x 2 x 2 cm cube located in the center of anterior cingulate cortex: an intermediate echo-time PRESS sequence and a 2D J-resolved averaged PRESS sequence. (Note: The 2D J-resolved averaged PRESS sequence was used for this outcome measure.) Spectroscopic data were inspected for quality; subjects whose data were contaminated by artifact were excluded from the study. Spectra were then processed using LCModel to quantify brain chemical levels. Regular brain MRI images were segmented, yielding a map of the amount of CSF in the head. The MRS voxel was overlaid onto the CSF map and the fraction of CSF within the voxel measured. This CSF-corrected measurement was then used for statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":".62"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":29},"commonTop":["Bruise on back of head near ossiput","Swollen lymph node","Rash on left knee","Abnormal high AST level at study exit","Abnormal high GGT level at study exit"]}}}